Sun Pharmaceutical Industries Ltd.

Sun Pharmaceuticals is currently trading at Rs. 485.50, up by 11.35 points or 2.39% from its previous closing of Rs. 474.15 on the BSE.

The scrip opened at Rs. 474.05 and has touched a high and low of Rs. 490.00 and Rs. 474.05 respectively. So far 37,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 538.45 on 26-Jul-2011 and a 52 week low of Rs. 341.10 on 17-Aug-2010.

Last one week high and low of the scrip stood at Rs. 490.00 and Rs. 473.00 respectively. The current market cap of the company is Rs. 50,275.00 crore.

The promoters holding in the company stood at 63.72% while Institutions and Non-Institutions held 25.59% and 10.70% respectively.

Sun Pharmaceutical Industries’ subsidiary has been granted a tentative approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Plavix, clopidogrel tablets USP.

These generic clopidogrel tablets USP, 75 mg are therapeutic equivalents of Sanofi Aventis’s Plavix tablets. Clopidogrel tablets USP have annual sale of approximately $6 billion in the US.

Clopidogrel tablets USP are indicated for the treatment of acute coronary syndrome, recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease.

Recently, the company’s had announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Uroxatral ER, alfuzosin hydrochloride extended release tablets